荷兰晚期黏膜黑色素瘤2013至2017年生存结局:全国人群研究
该研究基于荷兰黑色素瘤治疗注册数据库,纳入2013至2017年诊断的120例晚期黏膜黑色素瘤和2960例皮肤黑色素瘤患者,比较生存结局。黏膜黑色素瘤中位总生存为8.7个月,皮肤黑色素瘤为14.5个月;与皮肤黑色素瘤不同,黏膜黑色素瘤2015至2017年诊断者的总生存较2013至2014年未改善。
要点
- 晚期黏膜黑色素瘤预后差,中位总生存8.7个月,低于皮肤黑色素瘤的14.5个月
- 黏膜黑色素瘤一线免疫治疗比例77%,靶向治疗仅2%
- 黏膜黑色素瘤2015至2017年诊断者总生存较2013至2014年未改善
核心结论
- 在免疫和靶向治疗时代,晚期黏膜黑色素瘤的预后改善程度不及皮肤黑色素瘤。
研究设计与样本
- 基于荷兰黑色素瘤治疗注册数据库的全国人群队列研究,纳入2013至2017年诊断的晚期黏膜黑色素瘤120例和皮肤黑色素瘤2960例。
- 采用Kaplan-Meier法估计总生存,并在倾向评分匹配队列中分析,采用Cox模型分析预后因素与总生存的关联。
主要发现
- 黏膜黑色素瘤和皮肤黑色素瘤的中位总生存分别为8.7个月和14.5个月。
- 黏膜黑色素瘤患者中位年龄70岁、女性占60%,皮肤黑色素瘤分别为65岁和41%。
- 黏膜黑色素瘤一线免疫治疗和靶向治疗比例分别为77%和2%,皮肤黑色素瘤分别为49%和33%。
- 黏膜黑色素瘤2015至2017年诊断者总生存较2013至2014年诊断者未改善,而皮肤黑色素瘤有改善。
- 黏膜黑色素瘤中ECOG体力状态评分≥1与更差生存相关(HR=1.99 [1.26-3.15; p=0.003]),LDH升高亦相关(HR=1.63 [0.96-2.76]; p=0.069)。
临床怎么用
- 晚期黏膜黑色素瘤患者预后差,临床应关注ECOG评分≥1和LDH升高等不良预后因素。
- 黏膜黑色素瘤靶向治疗使用率低,需加强分子检测以识别可靶向突变。
局限性
- 黏膜黑色素瘤样本量较小(120例),可能限制统计效能。
- 研究为观察性注册研究,治疗选择可能存在混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatments are available for advanced melanoma. It is unclear whether patients with mucosal melanoma equally benefit from these new treatments compared with patients with cutaneous melanoma (CM). METHODS: Patients with advanced MM and CM diagnosed between 2013 and 2017 were included from a nationwide population-based registry - the Dutch Melanoma Treatment Registry. Overall survival (OS) was estimated with the Kaplan-Meier method (also for a propensity score-matched cohort). A Cox model was used to analyse the association of possible prognostic factors with OS. RESULTS: In total, 120 patients with MM and 2960 patients with CM were included. Median OS was 8.7 months and 14.5 months, respectively. Patients with MM were older (median age 70 versus 65 years) and more often female (60% versus 41%), compared with CM. In total, 77% and 2% of the MM patients were treated with first-line immunotherapy and targeted therapy, respectively, compared with 49% and 33% of the CM patients. In contrast to CM, OS for MM did not improve for patients diagnosed in 2015-2017, compared with 2013-2014. ECOG performance score ≥1 (HR = 1.99 [1.26-3.15; p = 0.003]) and elevated LDH level (HR = 1.63 [0.96-2.76]; p = 0.069) in MM were associated with worse survival. CONCLUSIONS: Within the era of immune and targeted therapies, prognosis for patients with advanced MM has not improved as much as for CM. Collaboration is necessary to enlarge sample size for research to improve immunotherapeutic strategies and identify targetable mutations.
引用
- van Zeijl MCT, Boer FL, van Poelgeest MIE, et al. Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. Eur J Cancer. 2020. PMID: 32763783. doi:10.1016/j.ejca.2020.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。